Doxorubicin Hydrochloride
Who holds supplier records for Doxorubicin Hydrochloride? 12 organisations hold a current record for Doxorubicin Hydrochloride: an active US FDA Type II Drug Master File or a CEP. A further 3 organisations have only historical (inactive) DMF filings. 11 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: China (2), Japan (2), India (1), Italy (1) and 4 other countries (4); not recorded for 2.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Doxorubicin Hydrochloride: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/doxorubicin-hydrochloride
Reading the evidence
- 12 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- 6 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
Current records (12)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Doxorubicin Hydrochloride. Country is the organisation's recorded country, not necessarily the manufacturing site.
- Zhejiang Hisun Pharmaceutical Co., Ltd.ChinaCEP Company GMP cert on recordActive DMF 27311, 13773 · latest filing Sept 2013
- DZD (Heze) Pharmaceutical Co., Ltd.ChinaCEP Company GMP cert on recordActive DMF 31153 · latest filing Nov 2016
- Intas Pharmaceuticals Ltd.IndiaCEP Company GMP cert on recordActive DMF 34545 · latest filing Jan 2020
- Meiji Seika Pharma Co., Ltd.JapanCEPActive DMF 13209 · latest filing Apr 1998
- MICROBIOPHARM JAPAN CO LTDJapanCEP Company GMP cert on recordActive DMF 13211 · latest filing Apr 1998
- OLON SPAItalyCEP Company GMP cert on recordActive DMF 30035 · latest filing Nov 2015
- SYNBIAS PHARMA AGSwitzerlandCEPActive DMF 16178 · latest filing Oct 2002
- TAPI NL BVNetherlandsCEPActive DMF 13726 · latest filing Sept 1998
- PHARMACIA AND UPJOHN CO WHOLLY OWNED SUB PFIZER INCActive DMF 2098 · latest filing Apr 1973
- STERLING BIOTECH LTDUnited StatesCEPActive DMF 24858 · latest filing Apr 2011
- BORYUNG PHARMACEUTICAL CO LTDCEP
- GermanyCEP Company GMP cert on record
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Valid CEP holder entries (11)
Certificates of Suitability on the EDQM register for Doxorubicin Hydrochloride, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 14 certificates in total, including withdrawn, expired, suspended and repeat certificates.
| Holder | Country | Certificate | Issued | EU GMP at holder's address |
|---|---|---|---|---|
| STERLING BIOTECH LIMITED Vadodara | IN | CEP 2012-039 - Rev 02 Doxorubicin Hydrochloride | Jun 2026 | — |
| INTAS PHARMACEUTICALS LIMITED Ahmedabad | IN | CEP 2012-367 - Rev 03 Doxorubicin Hydrochloride | Mar 2026 | — |
| TAPI NL B.V. Amsterdam | NL | CEP 2003-111 - Rev 07 Doxorubicin Hydrochloride | Jul 2025 | — |
| DZD (HEZE) PHARMACEUTICAL CO., LTD. Heze City | CN | CEP 2016-254 - Rev 01 Doxorubicin Hydrochloride | Jun 2025 | Inspected Nov 2023 Germany |
| Zhejiang Hisun Pharmaceutical Co., Ltd. Taizhou City | CN | CEP 1999-151 - Rev 09 Doxorubicin Hydrochloride | Oct 2024 | — |
| OLON S.P.A. Rodano | IT | CEP 2017-169 - Rev 04 Doxorubicin Hydrochloride | May 2024 | Inspected Mar 2025 Italy |
| TRANSO-PHARM HANDELS GMBH Siek | DE | R1-CEP 2004-059 - Rev 03 Doxorubicin Hydrochloride | Mar 2023 | — |
| SYNBIAS PHARMA AG Schaffhausen | CH | R0-CEP 2020-186 - Rev 00 Doxorubicin Hydrochloride | Sept 2022 | — |
| MEIJI SEIKA PHARMA CO., LTD. Tokyo | JP | R1-CEP 2003-151 - Rev 03 Doxorubicin Hydrochloride | Apr 2020 | — |
| BORYUNG PHARMACEUTICAL CO., LTD. Seoul | KR | R1-CEP 2010-324 - Rev 01 Doxorubicin Hydrochloride, Synthetic | Jul 2017 | — |
| MICROBIOPHARM JAPAN CO., LTD. Tokyo | JP | R1-CEP 2004-200 - Rev 05 Doxorubicin Hydrochloride | Mar 2017 | — |
The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.
Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.
Historical records (3)
Organisations whose Type II DMFs for Doxorubicin Hydrochloride are no longer active. These show a past filing, not current supply.
Show all 3 historical records
- India · Inactive DMF 24128 · filed Aug 2010
- France · Inactive DMF 18462 · filed Jun 2005
- United States · Inactive DMF 15514 · filed Jul 2001
Other forms of this substance
A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:
Overview
Doxorubicin Hydrochloride is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL359744).
Chemical identity
- IUPAC name
- (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride
- Canonical SMILES
- C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl
- InChIKey
- MWWSFMDVAYGXBV-RUELKSSGSA-N
- Synonyms
- Adriablastina cs, Adriamycin, Adriamycin, hydrochloride, Adriamycin pfs, Adriamycin rdf, Caelyx, Caelyx pegylated liposomal, Celdoxome pegylated liposomal, Doxil, Doxil (liposomal), Doxorubicin citrate, Doxorubicin citric acid salt
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Anthracycline Topoisomerase Inhibitor
- Mechanism of action
- Topoisomerase Inhibitors
- Chemical structure
- Anthracyclines
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Doxorubicin Hydrochloride?
12 organisations hold an active US FDA Type II Drug Master File or a CEP for Doxorubicin Hydrochloride: Zhejiang Hisun Pharmaceutical Co., Ltd. (China), DZD (Heze) Pharmaceutical Co., Ltd. (China), Intas Pharmaceuticals Ltd. (India), Meiji Seika Pharma Co., Ltd. (Japan), MICROBIOPHARM JAPAN CO LTD (Japan), OLON SPA (Italy), SYNBIAS PHARMA AG (Switzerland) and TAPI NL BV (Netherlands), and 4 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Doxorubicin Hydrochloride Drug Master Files are active?
Zhejiang Hisun Pharmaceutical Co., Ltd. (DMF 27311, 13773), DZD (Heze) Pharmaceutical Co., Ltd. (DMF 31153), Intas Pharmaceuticals Ltd. (DMF 34545), Meiji Seika Pharma Co., Ltd. (DMF 13209), MICROBIOPHARM JAPAN CO LTD (DMF 13211), OLON SPA (DMF 30035), SYNBIAS PHARMA AG (DMF 16178) and TAPI NL BV (DMF 13726) and 2 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
What do the historical Doxorubicin Hydrochloride records mean?
3 organisations have only inactive Type II DMFs for Doxorubicin Hydrochloride. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
Does Doxorubicin Hydrochloride have a European Certificate of Suitability?
Yes. 11 organisations hold a valid CEP for Doxorubicin Hydrochloride on the EDQM register, including STERLING BIOTECH LIMITED Vadodara (IN), INTAS PHARMACEUTICALS LIMITED Ahmedabad (IN), TAPI NL B.V. Amsterdam (NL), DZD (HEZE) PHARMACEUTICAL CO., LTD. Heze City (CN), Zhejiang Hisun Pharmaceutical Co., Ltd. Taizhou City (CN) and OLON S.P.A. Rodano (IT) and 5 more. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.
How do I qualify a Doxorubicin Hydrochloride supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Doxorubicin Hydrochloride?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.